These results could be confirmed for relapse-free survival (RFS) and disease-free survival (DFS) by other studies, i.e., the plasma cell marker CD38, among other markers of tumor-infiltrating lymphocytes, was used in a Japanese retrospective study including 114 patients with triple-negative breast cancer. This evidence concerns the gene CD38 and triple-negative breast carcinoma.